SPEAR T-cell Platform Delivers Initial Responses in Four Solid T
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
--------------------------------------------------------------
Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers.
--------------------------------------------------------------
Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors
----------------------------------------------------------
two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma.
----------------------------------------------------------
There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer
----------------------------------------------------------
These data further confirm the potential of Adaptimmune’s SPEAR T-cell platform for patients with multiple solid tumors.
----------------------------------------------------------
These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product-
----------------------------------------------------------
These are early results and we need more patient data and durability information to determine which therapies to develop.
www.adaptimmune.com/...ll-platform-delivers
--------------------------------------------------------------
Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers.
--------------------------------------------------------------
Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors
----------------------------------------------------------
two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma.
----------------------------------------------------------
There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer
----------------------------------------------------------
These data further confirm the potential of Adaptimmune’s SPEAR T-cell platform for patients with multiple solid tumors.
----------------------------------------------------------
These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product-
----------------------------------------------------------
These are early results and we need more patient data and durability information to determine which therapies to develop.
www.adaptimmune.com/...ll-platform-delivers